Market revenue in 2022 | USD 174.7 million |
Market revenue in 2030 | USD 565.1 million |
Growth rate | 15.8% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 67.09% in 2022. Horizon Databook has segmented the Middle East & Africa cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
In the Middle East region, regenerative medicine is currently used for wound & skin repair, sports medicine, or orthopedics. As compared to these fields, there are fewer products available for the treatment of cardiac diseases, cancers, and diabetes.
Over the last few years, clinics and hospitals in the region have been showing a growing interest in the cellular therapy space. For instance, in March 2019, Israel-based Sheba Medical and Lonza collaborated for manufacturing genetically engineered human Car-T cells. As part of this collaboration, Lonza is providing a manufacturing platform to bolster Sheba's in-house cell manufacturing processes.
Such collaborative efforts are anticipated to fuel growth of cell and gene therapy manufacturing in the region. Furthermore, countries such as Iran are witnessing an increasing adoption of stem cell therapies for research & therapeutic purposes.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cell and gene therapy manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account